Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
9.31
-1.07 (-10.31%)
Nov 2, 2026, 2:05 PM EST - Market open
Gossamer Bio Stock Forecast
GOSS's stock price has decreased by -95.13% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 8 analysts polled by S&P Global, Gossamer Bio stock has a consensus rating of "Buy" and an average price target of $95.4. The average 1-year stock price forecast is 924.70% higher than the current stock price, while the lowest is $22.4 (+140.60%) and the highest is $160 (+1,618.58%).
Price Target: $95.4 (+924.70%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Gossamer Bio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Buy Initiates $160 | Buy | Initiates | $160 | +1,618.58% | Oct 13, 2026 |
Unknown Analyst Guggenheim No rating | Guggenheim | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Sep 24, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $90 | Buy | Reiterates | $90 | +866.70% | Sep 21, 2026 |
| Wedbush | Wedbush | Hold Maintains $80 | Hold | Maintains | $80 | +759.29% | Aug 14, 2026 |
| Barclays | Barclays | Sell Maintains $22 | Sell | Maintains | $22 | +140.60% | Jul 28, 2026 |
Financial Forecast
Revenue This Year
40.51M
from 48.47M
Decreased by -16.43%
Revenue Next Year
16.73M
from 40.51M
Decreased by -58.71%
EPS This Year
-18.01
from -60.00
EPS Next Year
-15.61
from -18.01
EPS and Forward PE are based on non-GAAP adjusted numbers.